Semax: Published Research

Introduction

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide ACTH(4-10) analog with a peer-reviewed research body originating primarily from Russian academic institutions, with growing contributions from Western European and North American laboratories. The foundational finding in the published English-language literature — eightfold elevation of BDNF mRNA and fivefold elevation of NGF mRNA in rat glial cultures (Shadrina et al., 2001) [1] — established the melanocortin/neurotrophin axis as the primary mechanistic framework through which subsequent investigations have been organized. The published literature encompasses in vitro cell-culture studies, rodent neurochemical experiments, genome-wide transcriptional analyses, and preclinical model studies. This article summarizes findings from representative published studies. All findings are attributed to the cited primary sources. Researchers sourcing material for preclinical work can review the SpartaLabs Semax product page for batch-specific purity documentation.

Methodology Types in the Literature

Published Semax research spans four principal methodological categories:

In vitro cell culture: Multiple studies examined Semax's effects on neurotrophin gene expression or protein levels in isolated cell preparations — typically primary rat glial cultures, neuronal cultures, or established cell lines. These studies allow controlled examination of direct molecular interactions but do not account for pharmacokinetic variables including blood-brain barrier penetration, systemic distribution, or metabolic conversion. The molecular context for these interactions is detailed in the Semax mechanism of action article.

In vivo rodent neurochemistry: A substantial portion of the literature reports neurochemical measurements (monoamine metabolites, neurotrophin protein concentrations, receptor phosphorylation states) in rodents following peripheral or intranasal Semax administration. These studies provide systems-level pharmacological data but involve species that may not faithfully reproduce human pharmacology.

Transcriptome analysis: Genome-wide and targeted gene-expression studies in rodent models constitute a distinct methodological strand, examining how Semax modifies mRNA expression profiles in brain tissue rather than measuring specific molecular targets in isolation.

Behavioral pharmacology: A body of Russian-language research, partially available in English translation, characterized behavioral outcomes in rodent learning-and-memory paradigms. This article focuses on the molecular and neurochemical literature directly evaluable from English-language peer-reviewed publications.

Summary of Published Studies

Neurotrophin mRNA Induction in Vitro (Shadrina et al., 2001)

Shadrina and colleagues published the earliest English-language characterization of Semax's neurotrophin-regulatory effects in Neuroscience Letters in 2001 [1]. The study exposed primary rat glial cell cultures from neonatal basal forebrain to Semax in vitro and measured BDNF and NGF mRNA levels by quantitative PCR at 30 minutes post-treatment. The authors reported approximately eightfold elevation of BDNF mRNA and approximately fivefold elevation of NGF mRNA relative to vehicle controls — a magnitude the authors noted was larger than those observed for other pharmacological agents tested in the same model at that time. The study did not measure protein-level outcomes or establish receptor subtype involvement.

BDNF Protein and trkB Phosphorylation in Rat Hippocampus (Dolotov et al., 2006)

Dolotov and colleagues published two related papers in 2006 examining Semax's interaction with the BDNF/trkB axis in vivo. The Brain Research publication reported that a single Semax administration in adult rats was followed by approximately 1.4-fold elevation of BDNF protein, 3-fold elevation of exon III BDNF mRNA, and approximately 2-fold elevation of trkB mRNA in hippocampal tissue [2]. Tyrosine phosphorylation of trkB, a measure of receptor activation state, was also reported to be elevated approximately 1.6-fold. The study employed defined post-administration time points and used Western blotting and RT-PCR as primary measurement methods.

A companion paper in the Journal of Neurochemistry from the same group reported that Semax bound specifically to basal forebrain tissue preparations and that this binding was associated with changes in BDNF protein levels in that region [3]. The authors proposed that Semax's interaction with BDNF-related signaling in basal forebrain may involve mechanisms distinct from those operative in hippocampus, given the differing pharmacological profiles of those regions.

In Vivo Neurotrophin Gene Expression — Region Specificity (Agapova et al., 2007)

Agapova and colleagues published in vivo neurotrophin gene expression data in Neuroscience Letters in 2007, administering Semax intranasally to adult rats and measuring BDNF and NGF mRNA in hippocampus, frontal cortex, brainstem, cerebellum, and retina [4]. The study found that Semax-associated changes in neurotrophin gene expression were region-specific: BDNF mRNA expression showed changes in hippocampus, brainstem, and cerebellum, while NGF expression showed a directional decrease in frontal cortex at measured time points. The authors concluded that Semax engages a spatially patterned transcriptional response rather than uniform upregulation across brain regions.

Monoaminergic Pharmacology (Eremin et al., 2005)

Eremin and colleagues published neurochemical data in Neurochemical Research (2005) characterizing Semax's interaction with monoaminergic systems in rodents [5]. Using in vivo microdialysis and HPLC-electrochemical detection in striatum, frontal cortex, and hippocampus, the group measured dopamine, serotonin, and their major metabolites (DOPAC, HVA, 5-HIAA) at defined intervals following Semax administration. The authors reported altered monoamine turnover in all three regions examined and concluded that the observations were consistent with downstream effects of melanocortin receptor engagement. The study did not employ receptor-selective antagonist controls to confirm the MCR pathway as the proximate mechanism.

Basal Forebrain Cholinergic Neurons (Grivennikov et al., 2008)

Grivennikov and colleagues, writing in Restorative Neurology and Neuroscience (2008), reported in vitro data on Semax's effects on cholinergic neuron survival in rat basal forebrain cultures [6]. The authors reported approximately 1.5- to 1.7-fold changes in neuron survival counts relative to vehicle, using choline acetyltransferase (ChAT) immunostaining as the primary marker. This study was conducted in collaboration with Rutgers University in New Jersey — one of the early Western-Russian collaborative publications on the compound. The authors noted that the observed effects appeared to be mediated through a BDNF-dependent mechanism based on the culture conditions examined.

Genome-Wide Transcriptional Analysis in Focal Ischemia (Medvedeva et al., 2014)

Medvedeva and colleagues published a genome-wide transcriptional analysis in BMC Genomics (2014) using a permanent middle cerebral artery occlusion (pMCAO) rat model [7]. The study examined mRNA expression profiles in ischemic rat cortex at 3 hours and 24 hours after Semax administration, comparing gene expression relative to both sham-operated and vehicle-treated ischemia controls. Innate immune response pathways and genes associated with blood-brain barrier function showed the most pronounced differential expression at 24 hours, characterizing the transcriptional landscape of Semax's effects in this model.

Neurotrophin Transcription After Ischemia and the Pro-Gly-Pro Fragment (Dmitrieva et al., 2009)

Dmitrieva and colleagues, published in Cellular and Molecular Neurobiology (2009), specifically compared the transcriptional effects of intact Semax versus its C-terminal Pro-Gly-Pro metabolite in a rat ischemia model [8]. The study found that Semax showed a distinct selectivity pattern across neurotrophin gene targets (BDNF, trkB, trkC, trkA, NGF) compared to the Pro-Gly-Pro fragment, which the authors characterized as showing a less selective, broader transcriptional effect. This observation was interpreted as indicating that the pharmacological profile of Semax in vivo is not fully reducible to its metabolites — that the intact heptapeptide retains a distinct molecular selectivity.

Antistress Melanocortin Pharmacology (Inozemtseva et al., 2024)

Inozemtseva and colleagues published a chronic unpredictable stress (CUS) paradigm study in the European Journal of Pharmacology (2024), comparing Semax to Melanotan-II (another melanocortin analog) across behavioral and biochemical stress markers in male rats [9]. A comparable body of stress-model research has been published for the related Russian neuropeptide Selank, which similarly targets the melanocortin-adjacent anxiety and stress pharmacology space. The authors reported that chronic Semax administration was associated with attenuation of anhedonia measures (sucrose preference) and markers of chronic stress load (adrenal hypertrophy, body weight trajectory) compared to vehicle-treated CUS animals. Hippocampal BDNF protein levels were also reported to be altered by Semax treatment in the CUS context. The authors framed their findings within the melanocortin pharmacology framework, discussing ACTH(4-10) analogs as a class of noncorticotropic melanocortins with a distinct preclinical stress-response pharmacology.

Copper(II) Coordination and Cytotoxicity (Tabbì et al., 2015)

Tabbì and colleagues published in the Journal of Inorganic Biochemistry (2015), reporting that the N-terminal Met-Glu-His sequence in Semax forms a stable ATCUN-type complex with copper(II) ions [10]. In vitro experiments in SH-SY5Y neuroblastoma and RBE4 endothelial cell lines demonstrated that the Semax-copper complex showed reduced copper-induced cytotoxicity compared to copper alone. The authors proposed that this copper-chelating capacity could have pharmacological relevance in contexts of metal-ion dysregulation, opening an avenue distinct from the neurotrophin-centered mechanistic literature.

Spinal Cord Injury Model and Opioid Receptor (Liu et al., 2025)

Liu and colleagues published in the British Journal of Pharmacology (2025) a study examining Semax in a murine spinal cord injury (SCI) model, with a focus on the mu-opioid receptor gene Oprm1 [11]. The researchers reported that Semax was associated with functional recovery outcomes in female mice following SCI and that this was linked to regulation of the USP18 deubiquitinase pathway acting downstream of Oprm1. The study represents the first published characterization of Semax's interaction with opioid receptor signaling, extending the mechanistic literature beyond the melanocortin framework.

Areas of Ongoing Investigation

The published research on Semax identifies several active directions for the field:

Human data: No placebo-controlled, double-blinded clinical trial data on Semax pharmacokinetics, pharmacodynamics, or clinical outcomes in any indication has been published in indexed English-language peer-reviewed journals. The Russian regulatory approval was based on trial data that has not been made fully available in this form, representing a recognized gap that international research programs are positioned to address.

Receptor subtype specificity: The relative contributions of MC3R, MC4R, and other receptor subtypes to Semax's reported neurotrophin and monoaminergic effects have not been established using receptor-selective pharmacological tools or genetic models. This mechanistic question informs both target deconvolution and analog development.

Pharmacokinetics: The relationship between administered Semax quantities, CNS tissue concentrations, and receptor occupancy in vivo has not been rigorously quantified. Future pharmacokinetic characterization would strengthen interpretation of the existing efficacy literature.

Sex as a biological variable: Most published rodent studies used male animals exclusively. The 2025 Liu spinal cord injury study, conducted exclusively in female mice, noted sex-specific pharmacological interactions with Oprm1 signaling, suggesting that biological sex may modulate Semax's pharmacological profile in ways that warrant systematic investigation.

References

1. Shadrina MI, Dolotov OV, Grivennikov IA, Slominsky PA, Andreeva LA, Inozemtseva LS, Limborska SA, Myasoedov NF. Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neurosci Lett. 2001;308(2):115–8. PMID: 11457573. DOI: 10.1016/S0304-3940(01)01994-2

2. Dolotov OV, Karpenko EA, Seredenina TS, Inozemtseva LS, Levitskaya NG, Zolotarev YA, Kamensky AA, Grivennikov IA, Engele J, Myasoedov NF. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54–60. PMID: 16996037. DOI: 10.1016/j.brainres.2006.07.108

3. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Zolotarev YA, Kamensky AA, Grivennikov IA, Engele J, Myasoedov NF. Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97 Suppl 1:82–6. PMID: 16635254. DOI: 10.1111/j.1471-4159.2006.03658.x

4. Agapova TY, Agniullin YV, Shadrina MI, Shram SI, Kolomin TA, Myasoedov NF, Slominsky PA, Limborska SA. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10. Neurosci Lett. 2007;417(2):201–5. PMID: 17353092. DOI: 10.1016/j.neulet.2007.02.042

5. Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493–500. PMID: 16362768. DOI: 10.1007/s11064-005-8826-8

6. Grivennikov IA, Dolotov OV, Zolotarev YA, Andreeva LA, Myasoedov NF, Leacher L, Black IB, Dreyfus CF. Effects of behaviorally active ACTH(4-10) analogue Semax on rat basal forebrain cholinergic neurons. Restor Neurol Neurosci. 2008;26(1):35–43. PMID: 18431004. DOI: 10.3233/RNN-2008-00419

7. Medvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF, Dergunova LV. The peptide Semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. PMID: 24661604. PMCID: PMC3987924. DOI: 10.1186/1471-2164-15-228

8. Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010;30(1):71–9. PMID: 19633950. PMCID: PMC11498467. DOI: 10.1007/s10571-009-9432-0

9. Inozemtseva LS, Poletaeva DA, Dolotov OV, Grivennikov IA, Myasoedov NF. Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. Eur J Pharmacol. 2025;984:177068. PMID: 39442746. DOI: 10.1016/j.ejphar.2024.177068

10. Tabbì G, Magrì A, Giuffrida A, Lanza V, Pappalardo G, Naletova I, Nicoletti VG, Attanasio F, Rizzarelli E. Semax, an ACTH4-10 peptide analog with high affinity for copper(II) ion and protective ability against metal induced cell toxicity. J Inorg Biochem. 2015;142:39–46. PMID: 25310602. DOI: 10.1016/j.jinorgbio.2014.09.014

11. Liu Y, Chen X, Zhang Y, Wang H, Li Z, Wu J, et al. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. Br J Pharmacol. 2025. PMID: 40692165. DOI: 10.1111/bph.70122